INTRODUCTION AND OBJECTIVES: Cost-control initiatives targeting physicians are currently underway to improve cost-efficient clinical care. Little is known regarding surgeon-specific cost choices. We sought to characterize surgeon periorperative spending to evaluate the accuracy of a singular score summarizing surgeon costefficiency.
METHODS: All surgeons operating at UCSF Medical Center from July 2012-October 2015 across all specialties were included. Mean OR cost was calculated combining surgical supplies and time in the OR ($/minute). Cases were included if 4 surgeons performed said operation and all included surgeons completed 20 operations. Zscores, defined as [(cost of surgeon 0 s case) -(median cost for said case across all surgeons)] / [standard deviation (SD) of all surgeons 0 costs for said case], were calculated for each surgeon and surgical case performed. Estimated mean z-scores were then calculated using mixed effects modeling. Surgeons 0 z-score variability was evaluated using calculated SDs.
RESULTS: 257 surgeons across 17 surgical subspecialties were included in the analysis. The mean raw z-score was -0.12 ranging from -1.85 to 3.4 with SD of 0.78. The estimated z-score variability across the surgeons ranged from -0.5 to 0.5 SDs from the average estimated z-score (Figure 1 ). When comparing surgical subspecialties, the variability of z-scores ranged from 0.06 to -0.07. In individual subspecialties, the variability (SD) ranged from 0.25 to 0.02.
CONCLUSIONS: The z-score variability across all surgeons was small, supporting consistent surgeon-spending behavior across diverse cases. This supports using a surgeon 0 s estimated mean z-score as a singular and accurate metric characterizing surgeons 0 cost behavior. Given the volume and financial impact, radical prostatectomy (RP) will likely be targeted as episode-based payment policies expand. To date, there are no studies investigating non-index readmissions (hospital that did not perform the surgery) during 90-day RP episodes. Our objective was to compare the causes, outcomes, and hospital costs of patients with index vs. non-index readmissions following RP to better understand the impact of non-index readmissions in the 90-day RP episode.
Source of
METHODS: The 2013 Nationwide Readmissions Database was queried for prostate cancer patients undergoing RP. Sociodemographic characteristics, hospital costs, and causes of readmission were compared among index and non-index readmitted patients. Multivariable logistic regression models used to identify predictors of index, non-index, and subsequent readmission, prolonged length of stay (pLOS) upon readmission, and high-cost readmission.
RESULTS: While 5.4%(2154/39892) of patients were readmitted, their care accounted for 10.4% of perioperative (90 day CONCLUSIONS: This nationally representative study of RP patients demonstrates non-index readmissions are associated with comparable outcomes but higher hospital costs than index readmissions likely associated with differences in the rate and/or type of operative management. The benefits of undergoing RP at high-volume centers should be carefully balanced with the increased odds of nonindex readmissions and higher costs associated with them. As payers, providers, and patients continue to look for cost containment strategies and bundle the 90-day post hospitalization period, non-index readmissions are a potential target to decrease healthcare costs for RP patients.
Source of Funding: none
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